Quest Diagnostics' (DGX) New Study Exposes Alarming Data on STI

Zacks08-15

Quest Diagnostics DGX, in collaboration with the University of Alabama, conducted a study that suggests adherence to guideline-based laboratory testing and treatment of pregnant women for two of the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459475445?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UtFJmA2Sogt3ia9UtBrVtA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/90c6165961c32b679207868449ac44ae","is_english":true,"pubTime":"2024-08-15 21:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2459475445","market":"us","top_or_hot":-1,"title":"Quest Diagnostics' (DGX) New Study Exposes Alarming Data on STI","media":"Zacks","content":"<div>\n<p>Quest Diagnostics DGX, in collaboration with the University of Alabama, conducted a study that suggests adherence to guideline-based laboratory testing and treatment of pregnant women for two of the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/quest-diagnostics-dgx-study-exposes-130500845.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quest Diagnostics' (DGX) New Study Exposes Alarming Data on STI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuest Diagnostics' (DGX) New Study Exposes Alarming Data on STI\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-15 21:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/quest-diagnostics-dgx-study-exposes-130500845.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quest Diagnostics DGX, in collaboration with the University of Alabama, conducted a study that suggests adherence to guideline-based laboratory testing and treatment of pregnant women for two of the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/quest-diagnostics-dgx-study-exposes-130500845.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1548497426.USD","symbol_name":"安联环球人工智能AT Acc","start_time":0,"source_url":"https://finance.yahoo.com/news/quest-diagnostics-dgx-study-exposes-130500845.html","article_id":"2459475445","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UtFJmA2Sogt3ia9UtBrVtA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/90c6165961c32b679207868449ac44ae"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459475445","pubTimestamp":1723727100,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Quest Diagnostics DGX, in collaboration with the University of Alabama, conducted a study that suggests adherence to guideline-based laboratory testing and treatment of pregnant women for two of the most prevalent sexually transmitted infections  is suboptimal in the United States. This could potentially result in dire effects on maternal and newborn health.The study, titled “Chlamydia and gonorrhea testing in pregnancy: Time to improve adherence and update recommendations”, was published in the peer-reviewed Journal of Lower Genital Tract Disease — the official journal of the American Society for Colposcopy and Cervical Pathology. It is based on deidentified results of lab tests performed in all 50 states and the District of Columbia for more than four million pregnancies.Per key findings, more than 4% of women who received guideline-based screening for chlamydia or gonorrhea in pregnancy during the first trimester received a positive result for one or both infections. Among these, mo","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1548497426.USD":"安联环球人工智能AT Acc","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","IE00B19Z8W00.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH \"A\" INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4561":"索罗斯持仓","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0957791311.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"ZU\" (USD) ACC","TMO":"赛默飞世尔","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4548":"巴美列捷福持仓","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","DGX":"奎斯特诊疗","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU0342679015.USD":"ALLIANZ GLOBAL EQUITY UNCONSTRAINED \"AT\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","QGEN":"快而精医药","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1923622291.USD":"Natixis Thematics Safety R/A USD","PTRA":"Proterra Inc.","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU2041044095.USD":"Blackrock Circular Economy A2 USD","LU1633808545.USD":"ALLIANZ GLOBAL EQUITY GROWTH \"AT\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0096362180.USD":"CT (LUX) I GLOBAL FOCUS \"DU\" (USD)","HOLX":"豪洛捷","STI":"Solidion Technology Inc.","BK4196":"保健护理服务","BK4149":"建筑机械与重型卡车","LU0882574055.USD":"富达全球健康医疗A ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC"},"translate_title":"Quest Diagnostics(DGX)的新研究揭示了STI的惊人数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMO":1,"STI":1,"QGEN":1,"PTRA":1,"DGX":1,"HOLX":1},"content_text":"Quest Diagnostics DGX, in collaboration with the University of Alabama, conducted a study that suggests adherence to guideline-based laboratory testing and treatment of pregnant women for two of the most prevalent sexually transmitted infections (STIs) is suboptimal in the United States. This could potentially result in dire effects on maternal and newborn health.\nThe study, titled “Chlamydia and gonorrhea testing in pregnancy: Time to improve adherence and update recommendations”, was published in the peer-reviewed Journal of Lower Genital Tract Disease — the official journal of the American Society for Colposcopy and Cervical Pathology. It is based on deidentified results of lab tests performed in all 50 states and the District of Columbia for more than four million pregnancies.\nMore on the Study and Findings\nPer key findings, more than 4% of women who received guideline-based screening for chlamydia or gonorrhea in pregnancy during the first trimester received a positive result for one or both infections. Among these, more than one in three (35.1% chlamydia and 36.9% gonorrhea) did not receive a follow-up negative test before delivery. This reflects a possibility that they may not have been treated and cured or were treated and cured but then reinfected before birth.\nFurthermore, nearly 2% of patients who received a negative test result for chlamydia or gonorrhea early in pregnancy later tested positive, suggesting a persistent risk of infection during pregnancy. Of these patients, about one in two (53% chlamydia and 49.3% gonorrhea) remained positive prior to delivery.\nThe findings reveal gaps in guideline-based care intended to reduce the risk of infection and medical complications. Untreated chlamydia and gonorrhea can lead to heightened risks of infertility and pelvic inflammatory disease in women. The chance of transmission during birth is approximately 50%, raising the potential for newborns to develop infections of the eye (conjunctivitis), lungs (pneumonia) and other health problems.\nWhile the study benefits from its large size, national representation and use of objective laboratory data, it lacks the clinical follow-up information for the positive cases as testing was limited to one national clinical laboratory. The authors did not evaluate other STIs, such as syphilis. However, they caution that these patterns of irregular adherence to guideline-based testing in maternal care may extend to other conditions.\nConclusions of the Study\nThe authors of the study believe that reinfections (or ineffectively treated initial infections) may lead to more deliveries while women are positive for one or more STIs, affecting both maternal and newborn health. They also concluded that current guidelines are inconsistent and proposed several recommendations for improvements. For instance, the Centers for Disease Control and Prevention (“CDC”) recommends women be retested for cure at four weeks of pregnancy, while the USPSTF recommends retesting before three weeks.\nAdditionally, the present guidelines do not recommend screening women after the age of 25 years unless there are risk factors (such as multiple partners) based on much earlier data from 1988.\nThe guidelines recommend that all women under the age of 25 be screened, regardless of perceived risk.According to the CDC, the cases of sexually transmitted diseases are at an all-time high, with more than 2.5 million cases of syphilis, gonorrhea and chlamydia reported in the United States in 2022.\nIndustry Prospects\nPer a report by Grand View Research, the global STI testing market was valued at $10.1 billion in 2023 and is expected to witness a CAGR of 7.2% by 2030. The market is primarily influenced by advancements in diagnostic technology and increased government efforts to promote early detection and treatment.\nUpdates From Peers\nWithin the broader MedTech industry, several key players are involved in STI testing and diagnostics. These companies are also making other notable developments in their respective businesses.  \nWomen’s health-focused company, Hologic HOLX, dominates the U.S. markets for STI testing and is well-positioned to capture a larger share internationally. Last month, it acquired Endomagnetics Ltd (Endomag), the UK-based developer of breast cancer surgery technologies, in a transaction valued at approximately $310 million. The latter’s wireless breast surgery localization and lymphatic tracing solutions, including the Magseed marker, the Magtrace lymphatic tracer and the Sentimag platform, will complement and diversify Hologic’s expanding interventional breast health portfolio.\nRenowned for its Sample to Insight solutions, QIAGEN QGEN provides a range of STI tests through its Sexual & Reproductive Health portfolio, including tests for Chlamydia trachomatis and Neisseria gonorrhoeae infections. The company recently collaborated with the University of Montana to drive the implementation of next-generation sequencing and forensic investigative genetic genealogy in identifying human remains.\nFurthermore, it introduced 35 new wet-lab-tested digital PCR Microbial DNA Detection Assays for the QIAcuity digital PCR platform. These assays target pathogens responsible for tropical diseases, STIs and urinary tract infections, further solidifying the company’s leadership in microbial detection and analysis.\nAnother peer, Thermo Fisher Scientific TMO, offers several types of manual, automated or semi-automated in vitro diagnostic STI test kits and other STI testing products. The company’s SeCore CDx HLA A Sequencing System was recently granted the FDA 510(k) clearance as a companion diagnostic for Adaptimmune’s TECELRA (afamitresgene autoleucel) T-cell receptor therapy for unresectable or metastatic synovial sarcoma.\nTMO also introduced a novel pre-transplant risk assessment (PTRA) assay that helps assess the risk of early acute rejection in kidney transplant recipients. The One Lambda PTR Assay is the first test of its kind, aiming to help inform clinical decision-making and support more personalized patient management, with the ultimate aim of improving outcomes.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nQuest Diagnostics Incorporated (DGX) : Free Stock Analysis Report\nThermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report\nHologic, Inc. (HOLX) : Free Stock Analysis Report\nQIAGEN N.V. (QGEN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459475445"}